Cargando…
Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8651653/ https://www.ncbi.nlm.nih.gov/pubmed/34876566 http://dx.doi.org/10.1038/s41408-021-00590-5 |
| _version_ | 1784611444511211520 |
|---|---|
| author | Mina, Roberto Falcone, Antonietta Pia Bringhen, Sara Liberati, Anna Marina Pescosta, Norbert Petrucci, Maria Teresa Ciccone, Giovannino Capra, Andrea Patriarca, Francesca Rota-Scalabrini, Delia Bonello, Francesca Musolino, Caterina Cea, Michele Zambello, Renato Tacchetti, Paola Belotti, Angelo Cellini, Claudia Paris, Laura Grasso, Mariella Aquino, Sara De Paoli, Lorenzo De Sabbata, Giovanni Ballanti, Stelvio Offidani, Massimo Boccadoro, Mario Monaco, Federico Corradini, Paolo Larocca, Alessandra |
| author_facet | Mina, Roberto Falcone, Antonietta Pia Bringhen, Sara Liberati, Anna Marina Pescosta, Norbert Petrucci, Maria Teresa Ciccone, Giovannino Capra, Andrea Patriarca, Francesca Rota-Scalabrini, Delia Bonello, Francesca Musolino, Caterina Cea, Michele Zambello, Renato Tacchetti, Paola Belotti, Angelo Cellini, Claudia Paris, Laura Grasso, Mariella Aquino, Sara De Paoli, Lorenzo De Sabbata, Giovanni Ballanti, Stelvio Offidani, Massimo Boccadoro, Mario Monaco, Federico Corradini, Paolo Larocca, Alessandra |
| author_sort | Mina, Roberto |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8651653 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-86516532021-12-22 Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial Mina, Roberto Falcone, Antonietta Pia Bringhen, Sara Liberati, Anna Marina Pescosta, Norbert Petrucci, Maria Teresa Ciccone, Giovannino Capra, Andrea Patriarca, Francesca Rota-Scalabrini, Delia Bonello, Francesca Musolino, Caterina Cea, Michele Zambello, Renato Tacchetti, Paola Belotti, Angelo Cellini, Claudia Paris, Laura Grasso, Mariella Aquino, Sara De Paoli, Lorenzo De Sabbata, Giovanni Ballanti, Stelvio Offidani, Massimo Boccadoro, Mario Monaco, Federico Corradini, Paolo Larocca, Alessandra Blood Cancer J Correspondence Nature Publishing Group UK 2021-12-07 /pmc/articles/PMC8651653/ /pubmed/34876566 http://dx.doi.org/10.1038/s41408-021-00590-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correspondence Mina, Roberto Falcone, Antonietta Pia Bringhen, Sara Liberati, Anna Marina Pescosta, Norbert Petrucci, Maria Teresa Ciccone, Giovannino Capra, Andrea Patriarca, Francesca Rota-Scalabrini, Delia Bonello, Francesca Musolino, Caterina Cea, Michele Zambello, Renato Tacchetti, Paola Belotti, Angelo Cellini, Claudia Paris, Laura Grasso, Mariella Aquino, Sara De Paoli, Lorenzo De Sabbata, Giovanni Ballanti, Stelvio Offidani, Massimo Boccadoro, Mario Monaco, Federico Corradini, Paolo Larocca, Alessandra Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial |
| title | Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial |
| title_full | Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial |
| title_fullStr | Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial |
| title_full_unstemmed | Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial |
| title_short | Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial |
| title_sort | ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase ii, multi-arm, randomized unito-emn10 trial |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8651653/ https://www.ncbi.nlm.nih.gov/pubmed/34876566 http://dx.doi.org/10.1038/s41408-021-00590-5 |
| work_keys_str_mv | AT minaroberto ixazomibbasedinductionregimensplusixazomibmaintenanceintransplantineligiblenewlydiagnosedmultiplemyelomathephaseiimultiarmrandomizedunitoemn10trial AT falconeantoniettapia ixazomibbasedinductionregimensplusixazomibmaintenanceintransplantineligiblenewlydiagnosedmultiplemyelomathephaseiimultiarmrandomizedunitoemn10trial AT bringhensara ixazomibbasedinductionregimensplusixazomibmaintenanceintransplantineligiblenewlydiagnosedmultiplemyelomathephaseiimultiarmrandomizedunitoemn10trial AT liberatiannamarina ixazomibbasedinductionregimensplusixazomibmaintenanceintransplantineligiblenewlydiagnosedmultiplemyelomathephaseiimultiarmrandomizedunitoemn10trial AT pescostanorbert ixazomibbasedinductionregimensplusixazomibmaintenanceintransplantineligiblenewlydiagnosedmultiplemyelomathephaseiimultiarmrandomizedunitoemn10trial AT petruccimariateresa ixazomibbasedinductionregimensplusixazomibmaintenanceintransplantineligiblenewlydiagnosedmultiplemyelomathephaseiimultiarmrandomizedunitoemn10trial AT cicconegiovannino ixazomibbasedinductionregimensplusixazomibmaintenanceintransplantineligiblenewlydiagnosedmultiplemyelomathephaseiimultiarmrandomizedunitoemn10trial AT capraandrea ixazomibbasedinductionregimensplusixazomibmaintenanceintransplantineligiblenewlydiagnosedmultiplemyelomathephaseiimultiarmrandomizedunitoemn10trial AT patriarcafrancesca ixazomibbasedinductionregimensplusixazomibmaintenanceintransplantineligiblenewlydiagnosedmultiplemyelomathephaseiimultiarmrandomizedunitoemn10trial AT rotascalabrinidelia ixazomibbasedinductionregimensplusixazomibmaintenanceintransplantineligiblenewlydiagnosedmultiplemyelomathephaseiimultiarmrandomizedunitoemn10trial AT bonellofrancesca ixazomibbasedinductionregimensplusixazomibmaintenanceintransplantineligiblenewlydiagnosedmultiplemyelomathephaseiimultiarmrandomizedunitoemn10trial AT musolinocaterina ixazomibbasedinductionregimensplusixazomibmaintenanceintransplantineligiblenewlydiagnosedmultiplemyelomathephaseiimultiarmrandomizedunitoemn10trial AT ceamichele ixazomibbasedinductionregimensplusixazomibmaintenanceintransplantineligiblenewlydiagnosedmultiplemyelomathephaseiimultiarmrandomizedunitoemn10trial AT zambellorenato ixazomibbasedinductionregimensplusixazomibmaintenanceintransplantineligiblenewlydiagnosedmultiplemyelomathephaseiimultiarmrandomizedunitoemn10trial AT tacchettipaola ixazomibbasedinductionregimensplusixazomibmaintenanceintransplantineligiblenewlydiagnosedmultiplemyelomathephaseiimultiarmrandomizedunitoemn10trial AT belottiangelo ixazomibbasedinductionregimensplusixazomibmaintenanceintransplantineligiblenewlydiagnosedmultiplemyelomathephaseiimultiarmrandomizedunitoemn10trial AT celliniclaudia ixazomibbasedinductionregimensplusixazomibmaintenanceintransplantineligiblenewlydiagnosedmultiplemyelomathephaseiimultiarmrandomizedunitoemn10trial AT parislaura ixazomibbasedinductionregimensplusixazomibmaintenanceintransplantineligiblenewlydiagnosedmultiplemyelomathephaseiimultiarmrandomizedunitoemn10trial AT grassomariella ixazomibbasedinductionregimensplusixazomibmaintenanceintransplantineligiblenewlydiagnosedmultiplemyelomathephaseiimultiarmrandomizedunitoemn10trial AT aquinosara ixazomibbasedinductionregimensplusixazomibmaintenanceintransplantineligiblenewlydiagnosedmultiplemyelomathephaseiimultiarmrandomizedunitoemn10trial AT depaolilorenzo ixazomibbasedinductionregimensplusixazomibmaintenanceintransplantineligiblenewlydiagnosedmultiplemyelomathephaseiimultiarmrandomizedunitoemn10trial AT desabbatagiovanni ixazomibbasedinductionregimensplusixazomibmaintenanceintransplantineligiblenewlydiagnosedmultiplemyelomathephaseiimultiarmrandomizedunitoemn10trial AT ballantistelvio ixazomibbasedinductionregimensplusixazomibmaintenanceintransplantineligiblenewlydiagnosedmultiplemyelomathephaseiimultiarmrandomizedunitoemn10trial AT offidanimassimo ixazomibbasedinductionregimensplusixazomibmaintenanceintransplantineligiblenewlydiagnosedmultiplemyelomathephaseiimultiarmrandomizedunitoemn10trial AT boccadoromario ixazomibbasedinductionregimensplusixazomibmaintenanceintransplantineligiblenewlydiagnosedmultiplemyelomathephaseiimultiarmrandomizedunitoemn10trial AT monacofederico ixazomibbasedinductionregimensplusixazomibmaintenanceintransplantineligiblenewlydiagnosedmultiplemyelomathephaseiimultiarmrandomizedunitoemn10trial AT corradinipaolo ixazomibbasedinductionregimensplusixazomibmaintenanceintransplantineligiblenewlydiagnosedmultiplemyelomathephaseiimultiarmrandomizedunitoemn10trial AT laroccaalessandra ixazomibbasedinductionregimensplusixazomibmaintenanceintransplantineligiblenewlydiagnosedmultiplemyelomathephaseiimultiarmrandomizedunitoemn10trial |